recent articles
25 years ago when I started my clinical rotations as a third-year medical student, my interest in pathology across the medical and surgical specialties was usually met with a question such as "Why do you want to do pathology? You are going to...
Promega Corporation intends to seek FDA approval and CE-IVD marking for a commercially available Microsatellite Instability (MSI) assay to assist oncologists and pathologists in determining colorectal cancer decisions. The current Promega...
Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have...
© 2023 Tissuepathology.com. All rights reserved. Millennial Consulting. | Web Design by Zealth Digital Marketing